S2P Stock Overview
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Simcere Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.61 |
| 52 Week High | HK$1.16 |
| 52 Week Low | HK$0.57 |
| Beta | 0.46 |
| 1 Month Change | -3.94% |
| 3 Month Change | -5.43% |
| 1 Year Change | -47.41% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -57.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| S2P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -3.1% | -2.0% |
| 1Y | -47.4% | -31.9% | -0.3% |
Return vs Industry: S2P underperformed the German Pharmaceuticals industry which returned -31.9% over the past year.
Return vs Market: S2P underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| S2P volatility | |
|---|---|
| S2P Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: S2P has not had significant price volatility in the past 3 months.
Volatility Over Time: S2P's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 7,027 | Jinsheng Ren | www.simcere.com |
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets.
Simcere Pharmaceutical Group Limited Fundamentals Summary
| S2P fundamental statistics | |
|---|---|
| Market cap | €1.61b |
| Earnings (TTM) | €92.64m |
| Revenue (TTM) | €856.40m |
17.3x
P/E Ratio1.9x
P/S RatioIs S2P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S2P income statement (TTM) | |
|---|---|
| Revenue | CN¥6.61b |
| Cost of Revenue | CN¥1.62b |
| Gross Profit | CN¥4.98b |
| Other Expenses | CN¥4.27b |
| Earnings | CN¥714.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.28 |
| Gross Margin | 75.43% |
| Net Profit Margin | 10.82% |
| Debt/Equity Ratio | 16.9% |
How did S2P perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield58%
Payout RatioDoes S2P pay a reliable dividends?
See S2P dividend history and benchmarks| Simcere Pharmaceutical Group dividend dates | |
|---|---|
| Ex Dividend Date | Jun 18 2024 |
| Dividend Pay Date | Jul 15 2024 |
| Days until Ex dividend | 55 days |
| Days until Dividend pay date | 82 days |
Does S2P pay a reliable dividends?
See S2P dividend history and benchmarks